Description

Product information

IUPAC-name    4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine

Synonyms      Etizest, Etilaam, Etizex, Depas, Sedekopan, Pasaden, AHR 3219, Y-7131

Formal name    4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine

Cas number  40054-69-1

Formula     C₁₇H₁₅ClN₄S

Formula Weight    342.8

Purity     99.0 % min.

Formulations    A neat solid, Powder

Etizest, Etilaam, Etizex, Depas, Sedekopan, Pasaden, Etizolam, AHR 3219, Y-7131

The toxicological and physiological properties of this compound has not been analyzed. Usage of this Chemical should be for research and forensic purposes only.

Mechanism of Action

Positive allosteric modulation of GABA-A. Etizolam increases GABA’s effect at the chloride channel, reducing neuronal excitability. Class effects include anxiolysis, sedation/hypnosis, anticonvulsant activity, and muscle relaxation (1).

Onset and half-life. Labels and reviews abroad characterize a relatively rapid onset and shorter elimination half-life than diazepam (individual kinetics vary by age, liver function, formulation, and co-medications) (1)(3).

Tolerance and withdrawal. Repeated exposure can lead to GABA-A neuroadaptation, requiring higher doses for the same effect and risking withdrawal on abrupt cessation. Responsible labels recommend limiting duration, reassessing need, and tapering if used chronically (1)(3).

Interactions. Depressant effects add with alcohol and opioids, raising the risk of respiratory depression and prolonged sedation; public-health advisories warn against co-use (6)(7).

Effects, Benefits, and Risks

Intended effects (licensed contexts). Where prescribed, etizolam is used short-term for anxiety and sleep disorders, often in psychosomatic settings, with monitoring for efficacy and dependence (3).

Common adverse effects. Drowsiness, memory impairment, psychomotor slowing, and rebound insomnia/anxiety have been described. Risk increases with higher doses, co-depressants, hepatic impairment, or use outside labeled supervision (1).

Non-medical market realities. Canadian and UK sources report etizolam in counterfeit tablets and mixed “down” products; potency and co-exposures vary, increasing overdose risk. Harm-reduction responses include drug checking, alerts, and guidance on managing prolonged sedation (5)(7).

Do not mix with opioids or alcohol. Naloxone addresses the opioid component of an overdose but does not reverse benzodiazepines; observation may still be required (6).

Etizolam Withdrawal and Dependence

Dependence on etizolam arises through the same adaptive changes seen with other benzodiazepine-class compounds. Continuous modulation of the GABA-A receptor leads to receptor desensitization and neurochemical imbalance, creating a physiological reliance on the drug to maintain normal inhibitory tone. When exposure is reduced or stopped suddenly, this imbalance can trigger withdrawal, marked by symptoms such as rebound anxiety, insomnia, tremor, irritability, and in severe cases, seizures or delirium.

The risk and intensity of these effects depend on dose, duration of use, and the compound’s half-life. Because etizolam is relatively short-acting, withdrawal may emerge more rapidly and feel more acute than with longer-acting benzodiazepines. Combining etizolam with other CNS depressants—notably alcohol or opioids—greatly increases the danger of respiratory depression and delayed sedation, as naloxone reverses only the opioid component and leaves benzodiazepine effects intact.

Prescription labeling in countries where etizolam is approved, such as Japan, highlights limited treatment duration and mandatory reassessment intervals to reduce dependence risk. Outside these regulated settings, the situation becomes more unpredictable: counterfeit or mis-sold tablets often vary in potency or may contain other analogues, making withdrawal patterns inconsistent and increasing the likelihood of overdose.

Reducing harm requires a mix of scientific awareness, regulatory compliance, and public-health action. In research and clinical monitoring environments, this means verifying certificate-of-analysis (COA) documentation, ensuring lot traceability, and maintaining secure, lawful storage. Communities should emphasize no alcohol or opioid mixing, naloxone training, and early recognition of withdrawal signs. In clinical contexts, safe management follows benzodiazepine-class principles—gradual supervised reduction, careful monitoring, and supportive measures for anxiety or sleep disturbance—all within licensed medical frameworks.

Understanding these mechanisms and risk variables helps ensure safer handling of etizolam in every lawful context. For a detailed discussion of neuroadaptation, symptom progression, and harm-reduction strategies, continue to Etizolam Withdrawal & Dependence: Understanding the Risks.

Etizolam Dosage & Administration: Research Guidelines and Safety Tips

Our Etizolam dosage and administration guide explains how to measure, prepare, label, and store etizolam for research while staying inside legal and quality-system boundaries—no self-administration advice. You’ll learn how to select and operate calibrated analytical balances, perform drift/zero checks, and build traceable batch records with purity-corrected math and linked COAs (see USP/ISO 17025 references). The guide details volumetric preparation steps using Class A glassware or validated dispensers, labeling fields that matter (substance, concentration, expiry/retest, preparer/reviewer), and storage/security practices for controlled substances, including locked cabinets, restricted access, and audit-readiness.

Because market reports document counterfeit benzodiazepine tablets containing etizolam, the article stresses identity verification and instrumental analysis where appropriate. It also highlights interaction warnings: benzodiazepine-class drugs with opioids/alcohol increase overdose risk; naloxone treats the opioid component but does not reverse benzodiazepines—monitoring may still be needed. The Practical Checklist distills the workflow: verify legality, confirm COAs and traceability, document weighing and environment, apply conservative expiry/retest windows, and maintain a live training matrix and internal audits.

Use this post alongside the main hub, Etizolam: Complete Guide to Uses, Mechanism, Safety, and Legal Status, and related posts on Withdrawal & Dependence, Legal Status (2025 Update), Etizolam vs Diazepam, and Harm Reduction to keep teams aligned and compliant across the lifecycle of handling. You can read more here

Legal & Regulatory Status (2025)

United States. No FDA-approved indication. DEA temporarily placed etizolam and analogues into Schedule I (Jul 26, 2023) and proposed permanent Schedule I placement (Jul 25, 2025) (2) (8).

United Kingdom. Controlled as Class C under the Misuse of Drugs legislation; possession and supply attract penalties (4).

Canada. No licensed medical product; alerts document non-medical presence and overdose risks, especially with opioids (5)(6).

Japan. Prescription medicine (e.g., Depas), with dependence warnings and clinical monitoring per domestic labeling (3).

Bottom line. Check the current law in your jurisdiction and, where permitted, follow controlled-substance procedures (registration, inventory, storage, audits).

Etizolam vs. Classic Benzodiazepines

Etizolam shares the GABA-A mechanism with diazepam and alprazolam but is described abroad as having a faster onset and shorter half-life than diazepam; cross-tolerance within the class is expected. Any substitution or tapering should be clinician-directed in licensed settings only. In non-medical markets, counterfeit “benzodiazepines” may contain etizolam or other novel compounds, so authentic supply chains and drug checking matter for safety (1)(3)(5)(7).

If-This-Then-That: Safe-Handling Flow

• If your jurisdiction prohibits etizolam → Do not obtain or handle it; choose legal alternatives.

• If handling is allowed for registered research → Verify registration, maintain COAs, secure storage, training, and audit trails (2).

• If authenticity is uncertain → Use validated drug-checking or accredited lab testing and pause work until verified (5)(7).

Safe Handling & “Why Buy pure Etizolam From Us” (Lawful Jurisdictions Only)

Verification first. Confirm legality before any action. Require certificates of analysis (COAs), batch IDs, impurity profiles, and chain-of-custody documents from suppliers (5).

Measurement & storage. Use calibrated micro-balances, volumetric solutions, and tamper-evident containers. Maintain usage logs, expiry tracking, and deviation reports; restrict access to trained staff (2).

Why buy pure Etizolam from us (where lawful): Verified COAs, compliant logistics with discreet insured delivery, pharmacist input, and transparent pricing.

Important: We do not sell or ship where etizolam is prohibited or restricted. Buyers are responsible for confirming eligibility and maintaining full compliance.

Frequently Asked Questions

Is etizolam FDA-approved in the United States?
No. There are no FDA-approved indications; DEA actions since 2023 restrict handling (2) (8).

How does tolerance develop?
Repeated exposure drives GABA-A neuroadaptation, so higher doses may be needed for the same effect; abrupt cessation can trigger withdrawal (1).

How can I track legal changes?
Check Federal Register/DEA, gov.uk controlled drug lists, Health Canada/CCSA alerts, and PMDA labeling updates (2)(4)(7)(3).

Explore Our Etizolam Guides

• Etizolam Dosage & Administration: Research Guidelines and Safety Tips

• Etizolam Withdrawal & Dependence: Understanding the Risks

• Etizolam vs Diazepam: Pharmacological Comparison and Effects

• Etizolam Legal Status: Country-by-Country (2025 Update)

• Safe Etizolam Use & Harm Reduction Strategies

References

[1] WHO ECDD – Critical Review: Etizolam (2017). https://ecddrepository.org/en/etizolam
[2] U.S. Federal Register – Temporary Schedule I (Jul 26, 2023). https://www.federalregister.gov/documents/2023/07/26/2023-15748/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam
[3] PMDA / RAD-AR – Depas (Etizolam) drug information (Japan). https://www.rad-ar.or.jp/siori/english/search/result?n=44337
[4] UK Government – Controlled drugs list. https://www.gov.uk/government/publications/controlled-drugs-list–2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation
[5] BCCSU – Etizolam factsheet (Canada). https://www.bccsu.ca/wp-content/uploads/2022/06/Etizolam-Factsheet.pdf
[6] Alberta Health Services – Etizolam public notice. https://www.albertahealthservices.ca/assets/info/hrs/if-hrs-etizolam-public-notice.pdf
[7] CCSA / CCENDU – Nonmedical Benzodiazepines (2025). https://www.ccsa.ca/sites/default/files/2025-01/CCENDU-Newsletter-Issue-3-en.pdf
[8] U.S. Federal Register – Proposed permanent Schedule I (Jul 25, 2025). https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and

---

Medical/Legal Disclaimer: This page is for information and for law-compliant buyers or registered researchers only. Nothing here is medical advice or an encouragement to obtain controlled substances unlawfully. Always follow your jurisdiction’s laws.
Last reviewed: October 8, 2025 • Reviewer: Medical content editor (PharmD)

WARNING This product is not for human or veterinary use.

This product is only available to persons of 21 years old and above.

Hazard statement(s)

H302	Harmful if swallowed
H315	Causes skin irritation
H319	Causes serious eye irritation
H332	Harmful if inhaled
H335	cause respiratory irritation
H336	cause drowsiness or dizziness
Precautionary statement(s)
P264	Wash hands thoroughly after handling
P280	protective gloves/protective clothing/eye protection/face protection
P305 + P351 + P338	IF IN EYES: Rinse cautiously with for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313	If eye irritation persists: Get medical advice/attention
P261	Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray
P271	Use only outdoors or in a well-ventilated area
P304 + P340	IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P312	Call a POISON CENTER or doctor/physician if you feel unwell
P403 + P233	Store in a well-ventilated place. Keep container tightly closed
P405	Store locked up
P501	Dispose of contents/container to a licensed disposal company